WAVE Life Sciences Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), MoonLake Immunotherapeutics (MLTX) and Wave Life Sciences (WVE)
Analysts Are Bullish on These Healthcare Stocks: Wave Life Sciences (WVE), Dexcom (DXCM)
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), Brainsway (BWAY) and Wave Life Sciences (WVE)
WAVE Life Sciences Analyst Ratings
HC Wainwright & Co. Maintains Buy on WAVE Life Sciences, Raises Price Target to $15
Strategic Investment Boosts Wave Life Sciences: A Buy Rating Amidst Market Underappreciation
Leerink Partners Sticks to Its Buy Rating for Wave Life Sciences (WVE)
WAVE Life Sciences Analyst Ratings
Wave Life Sciences (WVE) Receives a Hold From Leerink Partners
Analysts Have Conflicting Sentiments on These Healthcare Companies: Wave Life Sciences (WVE), GoodRx Holdings (GDRX) and Axsome Therapeutics (AXSM)
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY), Wave Life Sciences (WVE) and AC Immune SA (ACIU)
RBC Capital Sticks to Its Hold Rating for Wave Life Sciences (WVE)
Wave Life Sciences: Buy Rating Based on Potential Pipeline Success and Key Catalysts for 2024
Promising RNAi Technology and Solid Financial Performance: A Buy Rating for Wave Life Sciences
Analysts Conflicted on These Healthcare Names: Fate Therapeutics (FATE), Wave Life Sciences (WVE) and HCA Healthcare (HCA)
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), Femasys (FEMY) and ImmunoGen (IMGN)
Watching Wave Life Sciences; Mizuho Note Says 'Wave Is Entering Obesity. INHBE Knockdown Led To 16% Weight Loss With Significant Decrease In Fat In 5 Weeks' Gives Buy Rating With $10 Price Target
Analysts' Top Healthcare Picks: Wave Life Sciences (WVE), Arcus Biosciences (RCUS)
Truist Financial Sticks to Their Buy Rating for Wave Life Sciences (WVE)
No Data